Repare Therapeutics (RPTX) AI Stock Analysis

• Market Cap: $92.25M
• Dividend Yield: N/A
• Average Volume (3M): 138.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.91
• Revenue Growth: -82.16%
• EPS Growth: 14.58%
• Country: US
• Employees: 129
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.08
• Shares Outstanding: 43,108,360
• 10 Day Avg. Volume: 221,679
• 30 Day Avg. Volume: 138,921
• PEG Ratio: 0.06
• Price to Book (P/B): 0.37
• Price to Sales (P/S): 1.04
• P/FCF Ratio: -0.73
• Enterprise Value/Market Cap: -0.53
• Enterprise Value/Revenue: -4.14
• Enterprise Value/Gross Profit: -4.81
• Enterprise Value/Ebitda: 0.68
• 1Y Price Target: $3.00
• Price Target Upside: 40.19% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 60 Neutral
• Price Target: $2.50 ▲(16.82% Upside)

Repare Therapeutics' overall stock score is driven by positive technical indicators and promising corporate developments, despite financial challenges and poor valuation metrics. The company's strong cash position and recent trial data provide a foundation for potential future improvements.

Positive Factors

Strong Cash Position

A strong cash position provides operational flexibility and the ability to invest in R&D, crucial for long-term growth in the biotech industry.

Promising Trial Data

Positive trial data enhances the company's pipeline credibility and potential for future product approvals, supporting long-term growth prospects.

Acquisition by XenoTherapeutics

The acquisition by XenoTherapeutics can provide strategic resources and support, potentially accelerating product development and market reach.

Negative Factors

Revenue Volatility

Significant revenue volatility indicates challenges in sustaining consistent income streams, affecting long-term financial stability.

Consistent Operating Losses

Ongoing operating losses suggest inefficiencies and may hinder the company's ability to achieve profitability, impacting long-term viability.

Negative Free Cash Flow

Negative free cash flow indicates the company is not generating sufficient cash from operations, which can constrain future investments and growth.

Repare Therapeutics Business Overview & Revenue Model

Company Description

Repare Therapeutics (RPTX) is a biotechnology company focused on the discovery and development of precision medicine for cancer treatment. The company leverages its proprietary synthetic lethality approach to identify and develop therapies targeting specific genetic vulnerabilities in tumors. Repare's core products include its lead drug candidates, which are designed to improve outcomes for patients with various cancer types by selectively targeting cancer cells while sparing healthy tissue.

How the Company Makes Money

Repare Therapeutics generates revenue primarily through the advancement of its drug candidates in clinical trials, leading to potential partnerships and licensing agreements with larger pharmaceutical companies. Key revenue streams include milestone payments from collaborators as drug candidates progress through development stages, royalties from sales of partnered products, and potential upfront payments from strategic alliances. The company's focus on synthetic lethality and precision oncology attracts interest from major players in the pharmaceutical industry, enhancing its potential for lucrative partnerships and collaborations that contribute to its earnings.

Repare Therapeutics Financial Statement Overview

Summary

Repare Therapeutics faces significant financial challenges with consistent losses and revenue volatility. Despite these issues, the balance sheet shows relative stability with a strong cash position and low leverage, providing some buffer for future operations.

Income Statement

Repare Therapeutics has shown significant revenue volatility over the years, with revenue dropping to zero in the most recent period from $51.13 million the previous year and $131.83 million two years prior. The company has consistently incurred operating losses, and negative net income, indicating ongoing profitability challenges. The EBIT and EBITDA margins are negative, reflecting operational inefficiencies. However, the company showed a brief revenue surge in 2022, which might indicate potential for recovery.

Balance Sheet

The company maintains a strong equity base relative to its liabilities, reflected in a low Debt-to-Equity ratio, which suggests stability. Despite consistent net losses, Repare's cash position remains robust, indicating prudent cash management. However, the Return on Equity is negative due to sustained net losses, which impacts overall shareholder returns negatively. The equity ratio has shown some decline but remains relatively healthy.

Cash Flow

Repare Therapeutics has faced challenges with negative free cash flow, although the cash flow from investing activities has been positive, largely due to asset management. The operating cash flow remains negative, indicating that the company is not generating enough cash from core operations to cover expenses. However, the company has managed to sustain cash reserves, which provides liquidity to continue operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.87M	53.48M	51.13M	131.83M	7.60M	135.00K
Gross Profit	10.23M	40.10M	37.89M	15.11M	-80.25M	-38.64M
EBITDA	-71.98M	-90.22M	-114.27M	-17.82M	-107.19M	-53.41M
Net Income	-72.20M	-84.69M	-93.80M	-29.05M	-106.91M	-53.42M
Balance Sheet
Total Assets	126.75M	176.51M	253.90M	364.07M	368.71M	357.09M
Cash, Cash Equivalents and Short-Term Investments	112.60M	152.79M	223.63M	343.94M	341.87M	333.71M
Total Debt	342.00K	1.93M	3.41M	5.43M	7.31M	4.00M
Total Liabilities	11.62M	25.38M	41.82M	84.56M	80.29M	70.26M
Stockholders Equity	115.13M	151.13M	212.08M	279.52M	288.42M	286.83M
Cash Flow
Free Cash Flow	-70.15M	-76.44M	-129.10M	-280.00K	-87.49M	-8.32M
Operating Cash Flow	-70.15M	-76.44M	-127.16M	322.00K	-85.80M	-6.08M
Investing Cash Flow	62.33M	49.47M	78.04M	-175.78M	-1.68M	-9.76M
Financing Cash Flow	110.00K	542.00K	842.00K	880.00K	95.56M	247.84M

Repare Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.14
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RPTX, the sentiment is Positive. The current price of 2.14 is below the 20-day moving average (MA) of 2.17, above the 50-day MA of 1.99, and above the 200-day MA of 1.57, indicating a bullish trend. The MACD of 0.06 indicates Positive momentum. The RSI at 60.69 is Neutral, neither overbought nor oversold. The STOCH value of 28.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RPTX.

Repare Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	60 Neutral	$92.25M	-1.31	-49.78%	―	-82.16%	14.58%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LTRN	45 Neutral	$36.46M	―	-104.58%	―	―	1.18%
GBIO	39 Underperform	$37.33M	-0.59	-80.81%	―	-17.82%	57.32%
PLRX	37 Underperform	$75.58M	-0.43	-64.27%	―	―	14.19%
PRLD	35 Underperform	$121.16M	-1.40	-103.99%	―	250.00%	15.15%
UNCY	28 Underperform	$119.49M	-1.80	-102.47%	―	―	66.05%

Repare Therapeutics Corporate Events

Repare Therapeutics announces CSO resignation and transition plan

On December 18, 2025, Repare Therapeutics announced that Chief Scientific Officer Michael Zinda, Ph.D., had resigned effective December 31, 2025, and entered into a separation agreement that provides nine months of salary, a retention payment, a 2025 target bonus, extended COBRA health coverage, accelerated vesting of certain equity awards, and an extended exercise window for vested stock options, alongside a three-month consulting arrangement at an hourly rate. The agreement also outlines enhanced change-in-control separation benefits that would replace the standard package if the planned acquisition of Repare by XenoTherapeutics or another qualifying change in control occurs on or shortly after his departure, underscoring both the company’s ongoing M&A process and the effort to manage executive transition and retention as shareholders prepare to vote on the Xeno deal at a special meeting on January 16, 2026.

Repare Therapeutics Announces Acquisition by XenoTherapeutics

Repare Therapeutics Inc. has entered into an Arrangement Agreement with XenoTherapeutics, Inc., wherein Xeno’s subsidiary will acquire all outstanding common shares of Repare. Shareholders will receive a cash payment per share and a contingent value right for potential future payments. The transaction, deemed fair and in the best interest of the company by its board, requires shareholder and court approvals and is subject to customary closing conditions.

Repare Therapeutics Unveils Phase 1 LIONS Trial Data

On October 22, 2025, Repare Therapeutics announced the availability of an abstract related to their Phase 1 LIONS trial of RP-1664. This preliminary data, showcasing the safety and antitumor activity of RP-1664 in advanced solid tumors, will be presented at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.